Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Medical Equipment/Device Sales
>
Zimmer
>
Amedica and Zimmer soon to be one
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="anonymous, post: 6012649"]More grasping & trying to distort the fact again from market makers (market manipulators), hedge funds managers & the et al...blah blah blah...</p><p><br /></p><p>As a matter of FACT, Amedica by itself will not be able to compete with big players out there & will not be able to gain meaningful market share on their own. Their <b><span style="color: #ff0000">MAIN JOB</span></b> was to <b><span style="color: #ff0000">VALIDATE</span></b> the Si3N4 biomaterial technologies for medical device applications (Spine, Hips, Knees, Dental, etc...). So their previous years, they focused on testing tech & testing the market & only pulled in tiny revenue...but not anymore. With the implementation of pre-acquisition talent integration, after <b>3 plus VPs from Zimmer joined them (as black ops)</b>, their revenue is back on track again:</p><p><br /></p><p><a href="https://amedicablog.wordpress.com/2018/02/22/q4-2017-revenue/" target="_blank" class="externalLink ProxyLink" data-proxy-href="https://amedicablog.wordpress.com/2018/02/22/q4-2017-revenue/" rel="nofollow">https://amedicablog.wordpress.com/2018/02/22/q4-2017-revenue/</a></p><p><br /></p><p>#s won't lie! Based on the calculations, with a sale team of less than 20 people (you said 30+ total employees, which is correct), $20 mils revenue in 2017 (<b>4Q = $9 mils to $12 mils = 300% - 400% increased - compares to 3Q' 2017 & 4Q' 2016</b>). This is evidence of the initial synergy at work from both (Zimmer & Amedica). Imagine the level of revenue can be generated once the tech is taken over by Zimmer & fully integrated with Zimmer's vast resources of sale channels & customer relationships. In addition, Japan region clearance is imminent as well & will bring in nice chunk of revenue too, not including revenue from future products. The total revenue will skyrocket..lucrative revenue streams for Zimmer later in time... <b><span style="color: #ff0000">Amedica has the tech... Zimmer has the resource to fully unlock the potential of the tech</span></b>. <b>PERFECT MARRIAGE</b>! Why the hate man? Hence, Hanson & his teams can't give proper guidance for the full year of 2018 yet (or could be a strategic reason - not leaking any info. before the announcement of the merger). See the connections of the dots? Of course you do, but I know you just want to distort the fact. You can attack the target company, but you can't stop the plans (for years) that Zimmer is trying to own this tech (await the validation on the tech, which is now is pretty much done).</p><p><br /></p><p>Now, look at the job opening at Amedica last few weeks:</p><p><br /></p><p><a href="https://www.indeed.com/viewjob?jk=ea4a52e1de37ab4d&from=companyalert&tk=1c7as0acvbqsnej5" target="_blank" class="externalLink ProxyLink" data-proxy-href="https://www.indeed.com/viewjob?jk=ea4a52e1de37ab4d&from=companyalert&tk=1c7as0acvbqsnej5" rel="nofollow">https://www.indeed.com/viewjob?jk=ea4a52e1de37ab4d&from=companyalert&tk=1c7as0acvbqsnej5</a></p><p><br /></p><p>See the job duties? The position is to assist & support the sales team - increase in sales - higher revenue! Again,<b> the increase in revenue only can be done by using the resources from Zimmer through their 3 black ops VP at Amedica</b>. Now back to reply to your grasping on "Sonny Bal fired half to save the company in 2016."...Please allow me to LMAO again! If AMDA is going solo, Sonny will reinstate the important positions like CFO, Controller, IR team, etc...right? Why didn't they? Because Zimmer already has:</p><p><br /></p><p>CFO - Dan Florin</p><p><br /></p><p>Controller - Tony Collins</p><p><br /></p><p>IR - Derek Davis</p><p><br /></p><p><a href="http://www.zimmerbiomet.com/corporate/about-zimmer-biomet/leadership.html" target="_blank" class="externalLink ProxyLink" data-proxy-href="http://www.zimmerbiomet.com/corporate/about-zimmer-biomet/leadership.html" rel="nofollow">http://www.zimmerbiomet.com/corporate/about-zimmer-biomet/leadership.html</a></p><p><br /></p><p>These reluctant positions are not necessary at Amedica as they are preparing themselves to be the bride to marry the groom, Zimmer! Also, the link also mentioned about <b>Amedica inventory level will only last until end of 2Q' 2018</b>. More sign of not going solo. This plays well with Hanson's 4Q' 2017 CC about connect with investors...through various events by then. It means once the deal is closed (announce March - April, close before 2Q ends), Zimmer will out source the manufacturing process of Si3N4 products with external vendors. See how the pieces of puzzle are clicked to each other? Complete analysis of Zimmer's 4Q' 2017 CC:</p><p><br /></p><p><a href="https://amedicablog.wordpress.com/2018/02/03/zimmers-q4-conference-call/" target="_blank" class="externalLink ProxyLink" data-proxy-href="https://amedicablog.wordpress.com/2018/02/03/zimmers-q4-conference-call/" rel="nofollow">https://amedicablog.wordpress.com/2018/02/03/zimmers-q4-conference-call/</a></p><p><br /></p><p>Now back to revenue discussion from the provided link.</p><p><br /></p><p>Amedica with a <b>sales team of less than 20</b>, the revenue ...</p><p><br /></p><p>In 2018, minimum est. <b>$4 - $5 mils / month</b>, which is roughly <b>$50 - 60 mils / year</b> not including the future revenue from Japan & other products, & regions...At this level, they are <b>possibly at break even point </b>or<b> even starting to profit</b> already. It is possibly will be an <b>accretive acquisition</b> for Zimmer:</p><p><br /></p><p><a href="https://www.investopedia.com/terms/a/accretiveacquisition.asp" target="_blank" class="externalLink ProxyLink" data-proxy-href="https://www.investopedia.com/terms/a/accretiveacquisition.asp" rel="nofollow">https://www.investopedia.com/terms/a/accretiveacquisition.asp</a></p><p><br /></p><p>as oppose to <b>LDRH acquisition 2016</b> - which was a <b>dilutive acquisition. </b>LDRH only helped Zimmer to pull in roughly <b>$170 mils per year</b> in Spine business even <b>after 5 quarters of integration</b> (LDHR revenue - prior acquisition was $160 mils per year already - lack of growth potential). Not helping much after all & Zimmer <b>paid $1 bil to acquire them</b>. </p><p><br /></p><p>The superior tech from <b>30-employee</b> tiny company transfers over to a company that is 600 times bigger (Zimmer has around <b>19K employees</b>). Can you imagine how much extra revenue this tech will help Zimmer in the long term??? </p><p><br /></p><p>Regarding future products & FDA approvals, Zimmer has the resource & political influences to easily obtain many future regulatory approvals for sure. Let's Hanson & his team worry about this.</p><p><br /></p><p>Regarding the grasping on "Zimmer has been slowly merging since 2011", yet again, Zimmer learned their mistake on Trabecular Metal, isn't it??? What make you think they don't want to make 1000000000000% sure that Si3N4 will not be like another TM again...hence the long plans for years - fully tested the tech first!!! Most importantly, the time to pull the trigger is close - based on Hanson's own words on 4Q' 2017 CC.[/QUOTE]</p><p><br /></p>
[QUOTE="anonymous, post: 6012649"]More grasping & trying to distort the fact again from market makers (market manipulators), hedge funds managers & the et al...blah blah blah... As a matter of FACT, Amedica by itself will not be able to compete with big players out there & will not be able to gain meaningful market share on their own. Their [B][COLOR=#ff0000]MAIN JOB[/COLOR][/B] was to [B][COLOR=#ff0000]VALIDATE[/COLOR][/B] the Si3N4 biomaterial technologies for medical device applications (Spine, Hips, Knees, Dental, etc...). So their previous years, they focused on testing tech & testing the market & only pulled in tiny revenue...but not anymore. With the implementation of pre-acquisition talent integration, after [B]3 plus VPs from Zimmer joined them (as black ops)[/B], their revenue is back on track again: [URL]https://amedicablog.wordpress.com/2018/02/22/q4-2017-revenue/[/URL] #s won't lie! Based on the calculations, with a sale team of less than 20 people (you said 30+ total employees, which is correct), $20 mils revenue in 2017 ([B]4Q = $9 mils to $12 mils = 300% - 400% increased - compares to 3Q' 2017 & 4Q' 2016[/B]). This is evidence of the initial synergy at work from both (Zimmer & Amedica). Imagine the level of revenue can be generated once the tech is taken over by Zimmer & fully integrated with Zimmer's vast resources of sale channels & customer relationships. In addition, Japan region clearance is imminent as well & will bring in nice chunk of revenue too, not including revenue from future products. The total revenue will skyrocket..lucrative revenue streams for Zimmer later in time... [B][COLOR=#ff0000]Amedica has the tech... Zimmer has the resource to fully unlock the potential of the tech[/COLOR][/B]. [B]PERFECT MARRIAGE[/B]! Why the hate man? Hence, Hanson & his teams can't give proper guidance for the full year of 2018 yet (or could be a strategic reason - not leaking any info. before the announcement of the merger). See the connections of the dots? Of course you do, but I know you just want to distort the fact. You can attack the target company, but you can't stop the plans (for years) that Zimmer is trying to own this tech (await the validation on the tech, which is now is pretty much done). Now, look at the job opening at Amedica last few weeks: [URL]https://www.indeed.com/viewjob?jk=ea4a52e1de37ab4d&from=companyalert&tk=1c7as0acvbqsnej5[/URL] See the job duties? The position is to assist & support the sales team - increase in sales - higher revenue! Again,[B] the increase in revenue only can be done by using the resources from Zimmer through their 3 black ops VP at Amedica[/B]. Now back to reply to your grasping on "Sonny Bal fired half to save the company in 2016."...Please allow me to LMAO again! If AMDA is going solo, Sonny will reinstate the important positions like CFO, Controller, IR team, etc...right? Why didn't they? Because Zimmer already has: CFO - Dan Florin Controller - Tony Collins IR - Derek Davis [URL]http://www.zimmerbiomet.com/corporate/about-zimmer-biomet/leadership.html[/URL] These reluctant positions are not necessary at Amedica as they are preparing themselves to be the bride to marry the groom, Zimmer! Also, the link also mentioned about [B]Amedica inventory level will only last until end of 2Q' 2018[/B]. More sign of not going solo. This plays well with Hanson's 4Q' 2017 CC about connect with investors...through various events by then. It means once the deal is closed (announce March - April, close before 2Q ends), Zimmer will out source the manufacturing process of Si3N4 products with external vendors. See how the pieces of puzzle are clicked to each other? Complete analysis of Zimmer's 4Q' 2017 CC: [URL]https://amedicablog.wordpress.com/2018/02/03/zimmers-q4-conference-call/[/URL] Now back to revenue discussion from the provided link. Amedica with a [B]sales team of less than 20[/B], the revenue ... In 2018, minimum est. [B]$4 - $5 mils / month[/B], which is roughly [B]$50 - 60 mils / year[/B] not including the future revenue from Japan & other products, & regions...At this level, they are [B]possibly at break even point [/B]or[B] even starting to profit[/B] already. It is possibly will be an [B]accretive acquisition[/B] for Zimmer: [URL]https://www.investopedia.com/terms/a/accretiveacquisition.asp[/URL] as oppose to [B]LDRH acquisition 2016[/B] - which was a [B]dilutive acquisition. [/B]LDRH only helped Zimmer to pull in roughly [B]$170 mils per year[/B] in Spine business even [B]after 5 quarters of integration[/B] (LDHR revenue - prior acquisition was $160 mils per year already - lack of growth potential). Not helping much after all & Zimmer [B]paid $1 bil to acquire them[/B]. The superior tech from [B]30-employee[/B] tiny company transfers over to a company that is 600 times bigger (Zimmer has around [B]19K employees[/B]). Can you imagine how much extra revenue this tech will help Zimmer in the long term??? [B][/B] Regarding future products & FDA approvals, Zimmer has the resource & political influences to easily obtain many future regulatory approvals for sure. Let's Hanson & his team worry about this. Regarding the grasping on "Zimmer has been slowly merging since 2011", yet again, Zimmer learned their mistake on Trabecular Metal, isn't it??? What make you think they don't want to make 1000000000000% sure that Si3N4 will not be like another TM again...hence the long plans for years - fully tested the tech first!!! Most importantly, the time to pull the trigger is close - based on Hanson's own words on 4Q' 2017 CC.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Medical Equipment/Device Sales
>
Zimmer
>
Amedica and Zimmer soon to be one
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Medical Equipment/Device Sales
>
Zimmer
>
Amedica and Zimmer soon to be one
>